Intra-procedural anticoagulation and post-procedural hemoglobin fall in atrial fibrillation ablation with minimally interrupted direct oral anticoagulants: comparisons across 4 drugs.
Activated clotting time
Atrial fibrillation ablation
Direct oral anticoagulants
Hemoglobin fall
Journal
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
22
06
2020
accepted:
12
08
2020
pubmed:
19
8
2020
medline:
24
8
2021
entrez:
19
8
2020
Statut:
ppublish
Résumé
Thromboembolic or hemorrhagic complications related to atrial fibrillation (AF) ablation are rare, and thus, it is difficult to compare their frequency across different direct oral anticoagulants (DOACs). We aimed to compare the intra-ablation blood coagulability and post-procedural hemoglobin fall as alternatives to those complications across 4 DOACs. We enrolled AF patients younger than 65 years old in 3 cardiovascular centers who skipped a single dose of apixaban, dabigatran, edoxaban, and rivaroxaban, prior to the ablation. Endpoints included the activated clotting time (ACT), heparin requirement during the ablation, and drop in the hemoglobin level 24 h after the procedure. The time-course curves of the ACT differed significantly across the patients with apixaban (N = 113), dabigatran (N = 130), edoxaban (N = 144), and rivaroxaban (N = 81), with its highest level in the dabigatran group (P < 0.001). The average ACT was greater in the dabigatran group than in the other groups (312.3 ± 34, 334.4 ± 44, 308.1 ± 41, and 305.8 ± 34.7 s; P < 0.001). A significant difference was noted in total heparin requirement across the patient groups (3990.2 ± 1167.9, 3890.4 ± 955.3, 4423.8 ± 1051.6, and 3972 ± 978.7 U/m A difference in DOACs may have an impact on intra-ablation anticoagulation; however, it may not be on the procedural blood loss in the setting of a single skip.
Identifiants
pubmed: 32808083
doi: 10.1007/s10840-020-00851-6
pii: 10.1007/s10840-020-00851-6
doi:
Substances chimiques
Anticoagulants
0
Hemoglobins
0
Pharmaceutical Preparations
0
Rivaroxaban
9NDF7JZ4M3
Dabigatran
I0VM4M70GC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
551-557Informations de copyright
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. Document Reviewers:. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20:e1–e160.
doi: 10.1093/europace/eux274
Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, et al. VENTURE-AF Investigators Uninterrupted rivaroxaban vs uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36:1805–11.
doi: 10.1093/eurheartj/ehv177
Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, et al. RE-CIRCUIT Investigators Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med. 2017;376:1627–36.
doi: 10.1056/NEJMoa1701005
Godier A, Dincq AS, Martin AC, Radu A, Leblanc I, Antona M, et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J. 2017;38:2431–9.
doi: 10.1093/eurheartj/ehx403
Sairaku A, Nakano Y, Onohara Y, Hironobe N, Matsumura H, Shimizu W, et al. Residual anticoagulation activity in atrial fibrillation patients with temporary interrupted direct oral anticoagulants: comparisons across 4 drugs. Thromb Res. 2019;183:119–23.
doi: 10.1016/j.thromres.2019.10.006
Mueller T, Alvarez-Madrazo S, Robertson C, Wu O, Bennie M. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. Br J Clin Pharmacol. 2019;85:422–31.
doi: 10.1111/bcp.13814
Silverio A, Di Maio M, Prota C, De Angelis E, Radano I, Citro R, et al. Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. 2019;12 Online ahead of print.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.
doi: 10.1378/chest.09-1584
O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36:3258–64.
pubmed: 26424865
pmcid: 4670965
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–93.
doi: 10.1093/eurheartj/ehy136
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
doi: 10.1056/NEJMoa1107039
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
doi: 10.1056/NEJMoa0905561
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.
doi: 10.1056/NEJMoa1310907
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
doi: 10.1056/NEJMoa1009638
Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J. 2013;77:632–8.
doi: 10.1253/circj.CJ-12-0899
Farmakis D, Davlouros P, Giamouzis G, Giannakoulas G, Pipilis A, Tsivgoulis G, et al. Direct oral anticoagulants in nonvalvular atrial fibrillation: practical considerations on the choice of agent and dosing. Cardiology. 2018;140:126–32.
doi: 10.1159/000489922
Watanabe R, Sairaku A, Yoshida Y, Nanasato M, Kamiya H, Suzuki H, et al. Head-to-head comparison of acute and chronic pulmonary vein stenosis for cryoballoon versus radiofrequency ablation. Pacing Clin Electrophysiol. 2018;41:376–82.
doi: 10.1111/pace.13293
Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation. 2014;129:2638–44.
doi: 10.1161/CIRCULATIONAHA.113.006426
Ebner M, Birschmann I, Peter A, Spencer C, Härtig F, Kuhn J, et al. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. Crit Care. 2017;21:32.
doi: 10.1186/s13054-017-1619-z
Martin AC, Kyheng M, Foissaud V, Duhamel A, Marijon E, Susen S, et al. Activated clotting time monitoring during atrial fibrillation catheter ablation: does the anticoagulant matter? J Clin Med. 2020;9:350.
doi: 10.3390/jcm9020350
Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11:756–60.
doi: 10.1111/jth.12149
Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest. 2017;151:127–38.
doi: 10.1016/j.chest.2016.08.1462
van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–27.
doi: 10.1160/TH09-11-0758
Sairaku A, Nakano Y, Kihara Y. Does dabigatran interfere with intraablation heparinization? Thromb Res. 2014;134:742–3.
doi: 10.1016/j.thromres.2014.06.026
Sairaku A, Onohara Y, Hironobe N, Matsumura H, Kihara Y, Nakano Y. Remaining activity of temporary interrupted direct oral anticoagulants and its impact on intra-ablation heparinization in patients with atrial fibrillation: comparisons across four drugs and two dose regimens. J Cardiovasc Electrophysiol. 2020;27 Online ahead of print.